CABA
Cabaletta Bio Inc
NASDAQ: CABA · HEALTHCARE · BIOTECHNOLOGY
$2.78
-2.80% today
Updated 2026-04-29
Market cap
$328.40M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.10
Dividend yield
—
52W range
$1 – $4
Volume
2.2M
Cabaletta Bio Inc (CABA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $104000.00 | $354000.00 | $733000.00 | $3.68M | $1.43M | $4.81M | $1.65M |
| Gross profit | — | — | $-104000.00 | $0.00 | $-733000.00 | $-3.68M | $-1.43M | $-4.81M | $-1.65M |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $4.46M | $4.47M | $11.67M | $21.38M | $32.49M | $39.30M | $55.42M | $97.20M | $142.67M |
| SG&A | $333333.00 | $1.73M | $7.01M | $12.46M | $13.82M | $14.84M | $19.24M | $27.94M | $29.57M |
| Operating income | $-250000.00 | $-6.19M | $-18.68M | $-33.83M | $-46.31M | $-54.14M | $-74.66M | $-125.14M | $-172.24M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $83333.00 | $-12.20M | $-18.58M | $-33.48M | $-45.58M | $-52.96M | $-66.25M | $-110.30M | $-170.59M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-250000.00 | $-6.19M | $-18.68M | $-33.83M | $-46.31M | $-54.14M | $-67.67M | $-115.12M | $-172.24M |
| Interest expense | $0.00 | $0.00 | $0.00 | $494000.00 | $733000.00 | $1.18M | $0.00 | $748000.00 | $2.00M |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-250000.00 | $-12.20M | $-15.10M | $-32.49M | $-45.53M | $-51.81M | $-67.67M | $-115.86M | $-167.86M |
| Net income growth (YoY) | — | -4780.8% | -23.7% | -115.2% | -40.1% | -13.8% | -30.6% | -71.2% | -44.9% |
| Profit margin | — | — | — | — | — | — | — | — | — |